Related Experiment Video
Updated: May 19, 2026

Vascular Occlusion Training for Inclusion Body Myositis: A Novel Therapeutic Approach
Published on: June 5, 2010
Pathogenesis and therapy of inclusion body myositis
1Division of Neuromuscular Disease, Department of Neurology, Brigham and Women's Hospital, and Children's Hospital Informatics Program Harvard Medical School, Boston, Massachusetts 02115, USA. sagreenberg@partners.org
Purpose Of Review:
Inclusion body myositis (IBM) is a poorly understood progressive muscle disease of middle and later life. Its dual pathologies of autoimmunity and unexplained myofiber degeneration and loss have been enigmatic since its earliest descriptions over 40 years ago. No reliable effective therapy currently exists for IBM. This review provides an update of current issues in the pathogenesis and therapy of IBM.
Recent Findings:
Recent studies have further defined the clinical features of IBM, including natural history, pattern of muscle involvement, and role of MRI imaging. Further potential immune mediators have been identified. An autoantibody directed against a muscle antigen appears to have high specificity for IBM among muscle diseases. Further evidence for myonuclear degeneration has been reported.
Summary:
IBM remains a poorly understood muscle disease, although understanding of the pathophysiological mechanisms continues to expand and is supporting new therapeutic approaches.
Related Concept Videos
Myocarditis I: Introduction
Myasthenia Gravis ll: Pathophysiology
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Myocarditis III: Medical Management
Myocarditis II: Clinical Features and Diagnostic Tests
Satellite Stem Cells and Muscular Dystrophy